Importance Dysregulated metabolism is a hallmark of renal cell carcinoma (RCC).
Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate.
Telaglenastat is an investigational, first-in-class, selective, oral glutaminase inhibitor that
blocks glutamine utilization and downstream pathways. Preclinically, telaglenastat
synergized with cabozantinib, a VEGFR2/MET/AXL inhibitor, in RCC models. Objective To
compare the efficacy and safety of telaglenastat plus cabozantinib (Tela+ Cabo) vs placebo …